RFK Jr.'s Peptide Push Could Hand Hims & Hers a Major Growth Opportunity

Hims & Hers Health may be poised for a significant business uplift as Robert F. Kennedy Jr.'s evolving health policy agenda shines a spotlight on peptide therapies, potentially opening new revenue streams for the telehealth company as it navigates a shifting GLP-1 landscape.

Peptides — short chains of amino acids used in treatments ranging from anti-aging to metabolic health — have long occupied a gray area in pharmaceutical regulation. With Kennedy at the helm of the Department of Health and Human Services, industry watchers say the regulatory environment could become more permissive, creating fertile ground for companies like Hims & Hers that already have compounding and direct-to-consumer infrastructure in place.

Hims & Hers built much of its recent momentum on compounded GLP-1 drugs, particularly semaglutide, which it offered at lower prices than branded alternatives like Ozempic and Wegovy. However, the FDA's ongoing review of the GLP-1 compounding market — expected to reach key decision points in 2026 — has introduced uncertainty about the long-term viability of that business segment.

Peptides could serve as a natural adjacency for the company. Analysts note that Hims & Hers already has the telehealth platform, the prescriber network, and the pharmacy partnerships necessary to scale a peptide offering relatively quickly if regulatory conditions align favorably.

The FDA's 2026 review timeline is seen as a pivotal moment. A more accommodating stance on peptide therapies under Kennedy's HHS could effectively greenlight broader commercial use, while a restrictive ruling could limit growth potential. Investors and industry observers are watching closely for signals from Washington that might clarify the regulatory trajectory.

For Hims & Hers, diversifying beyond GLP-1s is not just opportunistic — it may be strategic necessity. The company has faced pressure to demonstrate that its growth is not entirely dependent on compounded weight-loss drugs, and a thriving peptide business could help reassure investors about the durability of its revenue model.

As the regulatory and political landscape continues to evolve, Hims & Hers appears well-positioned to capitalize if the peptide opportunity materializes. Whether that potential translates into meaningful revenue will depend heavily on how federal health agencies respond to the growing demand for these therapies in the year ahead.